Compare Illumina, Inc. (ILMN) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nvidia Corp — how do they compare? Illumina, Inc. trades at $193.06 (market cap $29.12B), while Nvidia Corp trades at $219.95 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 181× Illumina, Inc.'s market cap, and Nvidia Corp pays a 0.46% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | NVDA | |
|---|---|---|
Market Cap | $29.12B | $5.27T |
Sector | Health | Technology |
52-Week High | $205.10 | $235.75 |
52-Week Low | $91.00 | $165.17 |
Enterprise Value | $30.48B | $5.20T |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVIDIA (NVDA) trades at $217.56, down 2.86% on the day, amid a broader tech sell-off. The stock maintains a bullish technical outlook with strong moving averages, though the 6-day RSI suggests overbought conditions near-term. Fundamentally, the company reported record revenue of $130.5B in 2025 with a net income margin of 62.97%, driven by AI chip demand. Recent earnings have consistently beaten estimates, and the company announced a $0.25 dividend payable in June 2026.
Outlook remains positive given NVIDIA's dominance in AI infrastructure, with a consensus price target of $325.86 implying significant upside. Risks include heightened valuations, competitive pressures, and macroeconomic sensitivity. Investor sentiment is buoyed by analyst optimism, with 75% recommending Buy, but news highlights concerns over growth sustainability as the company scales.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
